LOS ANGELES--(BUSINESS WIRE)--Hythiam, Inc. (Nasdaq:HYTM), a healthcare services management company that licenses the PROMETA® treatment protocols designed to treat alcohol, methamphetamine and cocaine dependence, announced today that the European Patent Office has notified the Company that it intends to grant a patent under Rule 51(4) EPC for Hythiam’s European Patent Application No. 02 711 879 3, which contains claims for the use of a composition of matter for the treatment of cocaine dependence.
